Ondine Announces Appointment of Dr. Timothy Rose as the Chairman of its Clinical Advisory Board

    VANCOUVER, Aug. 20 /CNW/ - Ondine Biopharma Corporation (TSX: OBP;
AIM: OBP) a medical technology company focused on photodisinfection
technology, announces that Dr. Timothy Rose, DDS has accepted the position as
chairman of its Clinical Advisory Board (CAB). Dr. Rose is a former president
of both the American Academy of Periodontology and the American Dental
Association. In addition to practising Periodontology in Wisconsin, Dr. Rose
also holds positions on various boards and committees. Over the course of his
career, Dr. Rose has received numerous prestigious awards in recognition of
his contributions to dentistry.
    "We are very pleased to have Dr. Rose take on the role as chairman of our
Clinical Advisory Board", said Carolyn Cross, President & CEO of Ondine.
"Dr. Rose's experience and expertise will be invaluable as Ondine expands its
development and commercialization efforts of Periowave(TM) and other
photodisinfection products."
    Ondine's Clinical Advisory Board members include: Dr. Steve Bruce
(General Dentist - Idaho), Dr. Greg Chadwick (Endodontist - North Carolina),
Dr. Sharon Compton (Director of Dental Hygiene Program - University of
Alberta), Dr. Richard Darveau (Professor - University of Washington),
Dr. Robert Genco (Periodontist - University of Buffalo), Professor Gareth
Griffiths (Professor, University of Sheffield) and Ms. Trisha O'Hehir (Editor
of Hygiene Town - Arizona). For more information about this board, please
visit the Company's website.

    About Periowave(TM) and Photodisinfection

    Periowave(TM) is a Photodisinfection system developed by Ondine that
utilizes low-intensity lasers and wavelength-specific, light-activated
photosensitive compounds to specifically target and destroy microbial
pathogens and reduce the symptoms of disease. The compounds are topically
applied and lasers of appropriate wavelength and intensity are used to
disinfect the treatment site.

    About Ondine Biopharma Corporation

    Ondine is developing non-antibiotic therapies for the treatment of a
broad spectrum of bacterial, fungal and viral infections. The Company is
focused on creating and commercializing leading-edge products utilizing its
patented light-activated technology. Photodisinfection provides broad-spectrum
antimicrobial efficacy without encouraging the formation and spread of
antibiotic resistance.
    The Company is headquartered in Vancouver, British Columbia, Canada, with
a research laboratory in Bothell, Washington, USA, and an international office
in St. Michael, Barbados. For additional information, please visit the
Company's website at: www.ondinebiopharma.com.

    Forward-Looking Statements:

    Certain statements contained in this release containing words like
"believe", "intend", "may", "expect" and other similar expressions, are
forward-looking statements that involve a number of risks and uncertainties.
Factors that could cause actual results to differ materially from those
projected in the Company's forward-looking statements include the following:
market acceptance of our technologies and products; our ability to obtain
financing; our financial and technical resources relative to those of our
competitors; our ability to keep up with rapid technological change;
government regulation of our technologies; our ability to enforce our
intellectual property rights and protect our proprietary technologies; the
ability to obtain and develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical milestones
in key products and other risk factors identified from time to time in the
Company's filings.

    The TSX Exchange has not reviewed and does not accept responsibility for
    the adequacy or accuracy of this release

For further information:

For further information: Carolyn Cross, President and Chief Executive
Officer, Ondine Biopharma Corporation, (604) 669-0555,
ccross@ondinebiopharma.com; Christina Bessant, Investor Relations, The Equicom
Group Inc., (416) 815-0700 ext. 269, cbessant@equicomgroup.com; Nominated
Adviser, Neil Johnson, Ryan Gaffney, Canaccord Adams Ltd, +44(0)20 7050 6500

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890